Drug intelligence / Profile preview

GKIND008A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules

Overview

GKIND008A is a preclinical-stage small molecule viral enzyme inhibitor being developed by China Resources Guokang Pharmaceutical. It is primarily targeted for the treatment of viral infections, specifically COVID-19 (SARS-CoV-2). The drug acts by inhibiting a viral enzyme essential for replication, although the specific enzyme (such as the 3CL protease or RNA-dependent RNA polymerase) has not been publicly disclosed in detail by the sponsor. As of 2024, the program is at the lead compound optimization stage.

Beyond the preview

Go deeper on GKIND008A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND008A.

Explore the full profile